Profile of veliparib and its potential in the treatment of solid tumors

被引：64

作者：

Wagner, Lars M. ^{[1
]}

机构：

[1] Univ Kentucky, Div Pediat Hematol Oncol, Lexington, KY 40536 USA

来源：

ONCOTARGETS AND THERAPY | 2015年 / 8卷

关键词：

veliparib; solid tumors; PARP inhibitor; BRCA; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; DRUG-DRUG INTERACTIONS; PARP INHIBITOR; PHASE-I; DNA-REPAIR; BREAST-CANCER; RADIATION-THERAPY; OVARIAN-CANCER; ABT-888; TEMOZOLOMIDE;

D O I：

10.2147/OTT.S69935

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Inhibition of poly(ADP-ribose) polymerase (PARP) is an attractive therapeutic strategy because of the importance of this pathway in restoring DNA damage. Small-molecule inhibitors of PARP appear most effective when used to treat tumors with underlying defects in DNA repair, or when combined with DNA-damaging agents. Veliparib is one of several recently developed oral inhibitors of PARP currently in clinical trials. This review summarizes the pharmacology, mechanisms of action, toxicity, and activity of veliparib seen in clinical trials to date. Also discussed are proposed mechanisms of resistance, potential biomarkers of activity, and issues regarding patient selection and combination therapies that may optimize use of this exciting new agent.

引用

页码：1931 / 1939

页数：9

共 59 条

[1] Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models [J].

Albert, Jeffrey M. ;

Cao, Carolyn ;

Kim, Kwang Woon ;

Willey, Christopher D. ;

Geng, Ling ;

Xiao, Dakai ;

Wang, Hong ;

Sandler, Alan ;

Johnson, David H. ;

Colevas, Alexander D. ;

Low, Jennifer ;

Rothenberg, Mace L. ;

Lu, Bo .

CLINICAL CANCER RESEARCH, 2007, 13 (10) :3033-3042

[2] Olaparib Approved for Advanced Ovarian Cancer [J].

不详 .

CANCER DISCOVERY, 2015, 5 (03) :218-218

[3]

[Anonymous], J CLIN ONCOL

[4] Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma [J].

Barazzuol, Lara ;

Jena, Raj ;

Burnet, Neil G. ;

Meira, Lisiane B. ;

Jeynes, Jonathan C. G. ;

Kirkby, Karen J. ;

Kirkby, Norman F. .

RADIATION ONCOLOGY, 2013, 8

[5] Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor [J].

Barber, Louise J. ;

Sandhu, Shahneen ;

Chen, Lina ;

Campbell, James ;

Kozarewa, Iwanka ;

Fenwick, Kerry ;

Assiotis, Ioannis ;

Rodrigues, Daniel Nava ;

Reis Filho, Jorge S. ;

Moreno, Victor ;

Mateo, Joaquin ;

Molife, L. Rhoda ;

De Bono, Johann ;

Kaye, Stan ;

Lord, Christopher J. ;

Ashworth, Alan .

JOURNAL OF PATHOLOGY, 2013, 229 (03) :422-429

[6] PARP Inhibitors Mechanism of Action and Their Potential Role in the Prevention and Treatment of Cancer [J].

Basu, Bristi ;

Sandhu, Shahneen K. ;

de Bono, Johann S. .

DRUGS, 2012, 72 (12) :1579-1590

[7] PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma [J].

Brenner, J. Chad ;

Feng, Felix Y. ;

Han, Sumin ;

Patel, Sonam ;

Goyal, Siddharth V. ;

Bou-Maroun, Laura M. ;

Liu, Meilan ;

Lonigro, Robert ;

Prensner, John R. ;

Tomlins, Scott A. ;

Chinnaiyan, Arul M. .

CANCER RESEARCH, 2012, 72 (07) :1608-1613

[8]

Coleman RL., 2015, Gynecol Oncol

[9] ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models [J].

Donawho, Cherrie K. ;

Luo, Yan ;

Luo, Yanping ;

Penning, Thomas D. ;

Bauch, Joy L. ;

Bouska, Jennifer J. ;

Bontcheva-Diaz, Velitchka D. ;

Cox, Bryan F. ;

DeWeese, Theodore L. ;

Dillehay, Larry E. ;

Ferguson, Debra C. ;

Ghoreishi-Haack, Nayereh S. ;

Grimm, David R. ;

Guan, Ran ;

Han, Edward K. ;

Holley-Shanks, Rhonda R. ;

Hristov, Boris ;

Idler, Kenneth B. ;

Jarvis, Ken ;

Johnson, Eric F. ;

Kleinberg, Lawrence R. ;

Klinghofer, Vered ;

Lasko, Loren M. ;

Liu, Xuesong ;

Marsh, Kennan C. ;

McGonigal, Thomas P. ;

Meulbroek, Jonathan A. ;

Olson, Amanda M. ;

Palma, Joann P. ;

Rodriguez, Luis E. ;

Shi, Yan ;

Stavropoulos, Jason A. ;

Tsurutani, Alan C. ;

Zhu, Gui-Dong ;

Rosenberg, Saul H. ;

Giranda, Vincent L. ;

Frost, David J. .

CLINICAL CANCER RESEARCH, 2007, 13 (09) :2728-2737

[10] Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer [J].

Duan, Wenrui ;

Gao, Li ;

Aguila, Brittany ;

Kalvala, Arjun ;

Ottersoe, Gregory A. ;

Villalona-Calero, Miguel A. .

FRONTIERS IN ONCOLOGY, 2014, 4

← 1 2 3 4 5 6 →